Workflow
Avista Q4 Earnings Call Highlights
Yahoo Finance· 2026-02-26 14:16
On the regulatory front, Christie said Avista filed a four-year rate plan with the Washington Utilities and Transportation Commission in January. He said the “single largest driver” of the requested rate increase in the first rate year is power supply cost , and he emphasized that establishing an appropriate baseline for power supply costs is central to the plan’s success. Avista expects the initial settlement conference on May 22 and evidentiary hearings on September 17 and 18 .CFO Kevin Christie also addr ...
Grupo Aeroportuario del Sureste Q4 Earnings Call Highlights
Yahoo Finance· 2026-02-26 14:16
Grupo Aeroportuario del Sureste logo Grupo Aeroportuario del Sureste (NYSE:ASR) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight a “key inflection point” for the airport operator, pointing to new diversification initiatives alongside softer traffic trends in some markets and the impact of currency movements on reported results. Strategic moves: U.S. acquisition and pending Motiva deal Chief Executive Officer Adolfo Castro said ASUR completed its expansion into ...
Aspen Aerogels Q4 Earnings Call Highlights
Yahoo Finance· 2026-02-26 14:16
Maintenance and turnarounds: Young cited pent-up demand from refinery and petrochemical end users that have run facilities hard while minimizing maintenance and turnarounds.LNG and natural gas infrastructure: Young said the LNG market is in a multi-year build cycle and that Aspen expects its LNG and natural gas infrastructure activity in 2026 to roughly double versus 2025 in both project count and revenue contribution. He said Aspen is positioned across the entire LNG value chain, not solely liquefaction.Su ...
Collegium Pharmaceutical Q4 Earnings Call Highlights
Yahoo Finance· 2026-02-26 14:16
Chief Commercial Officer Scott Dreyer said Jornay delivered record prescription volume in both the fourth quarter and full year 2025. In the fourth quarter, more than 200,000 prescriptions were written, up 16% year-over-year, and more than 760,000 prescriptions were written in 2025, up 20%. Dreyer added that average weekly prescriptions increased to approximately 16,600 in December from about 13,800 in July, and he said momentum continued into January at approximately 16,800 weekly prescriptions despite typ ...
American Bitcoin Q4 Earnings Call Highlights
Yahoo Finance· 2026-02-26 14:16
American Bitcoin logo The Great Pivot: Bitcoin Miners Are Becoming AI’s Landlords American Bitcoin (NASDAQ:ABTC) executives used the company’s fourth-quarter and full-year 2025 earnings call to emphasize rapid balance-sheet growth, a low-cost mining strategy, and what management described as a “dual accumulation” model that combines Bitcoin mining with treasury purchases. Co-founder and Chief Strategy Officer Eric Trump said the company launched on March 31, 2025, went public on Sept. 3, and has gro ...
ACI Worldwide (ACIW) Misses Q4 Earnings Estimates
ZACKS· 2026-02-26 14:16
分组1 - ACI Worldwide reported quarterly earnings of $0.9 per share, missing the Zacks Consensus Estimate of $1.05 per share, and down from $1.08 per share a year ago, representing an earnings surprise of -14.29% [1] - The company posted revenues of $481.6 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.82%, and up from $453.04 million year-over-year [2] - ACI Worldwide has surpassed consensus revenue estimates four times over the last four quarters [2] 分组2 - ACI Worldwide shares have declined approximately 13.2% since the beginning of the year, while the S&P 500 has gained 1.5% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for ACI Worldwide was unfavorable ahead of the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] 分组3 - The current consensus EPS estimate for the upcoming quarter is $0.34 on revenues of $402.2 million, and for the current fiscal year, it is $3.41 on revenues of $1.87 billion [7] - The Computer - Software industry, to which ACI Worldwide belongs, is currently in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]
These Analysts Slash Their Forecasts On Snowflake After Q4 Results - Snowflake (NYSE:SNOW)
Benzinga· 2026-02-26 14:16
Snowflake Inc (NYSE:SNOW) posted better-than-expected financial results for the fourth quarter of fiscal 2026 after the close on Wednesday.Snowflake reported fourth-quarter revenue of $1.28 billion, beating analyst estimates of $1.26 billion, according to Benzinga Pro. The company reported adjusted earnings of 34 cents per share for the quarter, beating analyst estimates of 27 cents per share."This past year has been transformative for every business, as the promise of AI became real, and Snowflake sits at ...
Victory Capital submits $57 per share rival bid for Janus Henderson
Reuters· 2026-02-26 14:16
Victory Capital said on Thursday it has offered to buy peer Janus Henderson for $57.04 per share, months after the asset manager unveiled a $7.4 billion deal with Nelson Peltz's Trian and VC firm Gene... ...
These Analysts Slash Their Forecasts On Snowflake After Q4 Results
Benzinga· 2026-02-26 14:16
Snowflake Inc (NYSE:SNOW) posted better-than-expected financial results for the fourth quarter of fiscal 2026 after the close on Wednesday.Snowflake reported fourth-quarter revenue of $1.28 billion, beating analyst estimates of $1.26 billion, according to Benzinga Pro. The company reported adjusted earnings of 34 cents per share for the quarter, beating analyst estimates of 27 cents per share."This past year has been transformative for every business, as the promise of AI became real, and Snowflake sits at ...
Aurinia Pharmaceuticals (AUPH) Tops Q4 Earnings and Revenue Estimates
ZACKS· 2026-02-26 14:16
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +25.79%. A quarter ago, it was expected that this biotechnology company would post earnings of $0.16 per share when it actually produced earnings of $0.23, delivering a surprise of +43.75%.Over the last fou ...